Androgen receptor and antiandrogen therapy in male breast cancer

Luigi Di Lauro, Maddalena Barba, Laura Pizzuti, Patrizia Vici, Domenico Sergi, Anna Di Benedetto, Marcella Mottolese, Valerie Speirs, Daniele Santini, Ruggero De Maria, Marcello Maugeri-Saccà

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Cancers arising in the male breast are uncommon. Male breast cancer is a hormone-driven disease that often expresses the estrogen receptor, and antiestrogen therapy represents the mainstay of treatment. Paradoxically, the advent of a wave of antiestrogens eclipsed the therapeutic potential of alternative therapeutic options. At the beginning of the hormonal therapy era the administration of antiandrogens to metastatic male breast cancer patients was proposed. Ever since the use of these compounds has largely been neglected. A therapeutic role for antiandrogens has been envisioned again in recent years. First, molecular characterization efforts pointed to the androgen receptor as a potential therapeutic target. Second, the development of aromatase inhibitors unexpectedly raised the need for neutralizing androgens in order to tackle endocrine feedback mechanisms responsible for acquired resistance. We herein provide an overview of molecular studies where the androgen receptor was investigated at the genomic, transcriptomic or phenotypic level. We then discuss androgens in the context of the endocrine networks nourishing male breast cancer. Finally, clinical evidence on antiandrogens is summarized along with strategies should be implemented to improve the medical management of these patients.

Original languageEnglish
Pages (from-to)20-25
Number of pages6
JournalCancer Letters
Volume368
Issue number1
Early online date11 Aug 2015
DOIs
Publication statusPublished - 1 Nov 2015

Fingerprint

Male Breast Neoplasms
Androgen Antagonists
Androgen Receptors
Estrogen Receptor Modulators
Therapeutics
Androgens
Aromatase Inhibitors
Estrogen Receptors
Breast
Hormones

Keywords

  • Androgen Antagonists
  • Animals
  • Antineoplastic Agents, Hormonal
  • Breast Neoplasms, Male
  • Humans
  • Male
  • Molecular Targeted Therapy
  • Neoplasms, Hormone-Dependent
  • Receptors, Androgen
  • Signal Transduction
  • Treatment Outcome
  • Journal Article
  • Review

Cite this

Di Lauro, L., Barba, M., Pizzuti, L., Vici, P., Sergi, D., Di Benedetto, A., ... Maugeri-Saccà, M. (2015). Androgen receptor and antiandrogen therapy in male breast cancer. Cancer Letters, 368(1), 20-25. https://doi.org/10.1016/j.canlet.2015.07.040

Androgen receptor and antiandrogen therapy in male breast cancer. / Di Lauro, Luigi; Barba, Maddalena; Pizzuti, Laura; Vici, Patrizia; Sergi, Domenico; Di Benedetto, Anna; Mottolese, Marcella; Speirs, Valerie; Santini, Daniele; De Maria, Ruggero; Maugeri-Saccà, Marcello.

In: Cancer Letters, Vol. 368, No. 1, 01.11.2015, p. 20-25.

Research output: Contribution to journalReview article

Di Lauro, L, Barba, M, Pizzuti, L, Vici, P, Sergi, D, Di Benedetto, A, Mottolese, M, Speirs, V, Santini, D, De Maria, R & Maugeri-Saccà, M 2015, 'Androgen receptor and antiandrogen therapy in male breast cancer', Cancer Letters, vol. 368, no. 1, pp. 20-25. https://doi.org/10.1016/j.canlet.2015.07.040
Di Lauro L, Barba M, Pizzuti L, Vici P, Sergi D, Di Benedetto A et al. Androgen receptor and antiandrogen therapy in male breast cancer. Cancer Letters. 2015 Nov 1;368(1):20-25. https://doi.org/10.1016/j.canlet.2015.07.040
Di Lauro, Luigi ; Barba, Maddalena ; Pizzuti, Laura ; Vici, Patrizia ; Sergi, Domenico ; Di Benedetto, Anna ; Mottolese, Marcella ; Speirs, Valerie ; Santini, Daniele ; De Maria, Ruggero ; Maugeri-Saccà, Marcello. / Androgen receptor and antiandrogen therapy in male breast cancer. In: Cancer Letters. 2015 ; Vol. 368, No. 1. pp. 20-25.
@article{ad6c2f085d1d415b90861b54732667f2,
title = "Androgen receptor and antiandrogen therapy in male breast cancer",
abstract = "Cancers arising in the male breast are uncommon. Male breast cancer is a hormone-driven disease that often expresses the estrogen receptor, and antiestrogen therapy represents the mainstay of treatment. Paradoxically, the advent of a wave of antiestrogens eclipsed the therapeutic potential of alternative therapeutic options. At the beginning of the hormonal therapy era the administration of antiandrogens to metastatic male breast cancer patients was proposed. Ever since the use of these compounds has largely been neglected. A therapeutic role for antiandrogens has been envisioned again in recent years. First, molecular characterization efforts pointed to the androgen receptor as a potential therapeutic target. Second, the development of aromatase inhibitors unexpectedly raised the need for neutralizing androgens in order to tackle endocrine feedback mechanisms responsible for acquired resistance. We herein provide an overview of molecular studies where the androgen receptor was investigated at the genomic, transcriptomic or phenotypic level. We then discuss androgens in the context of the endocrine networks nourishing male breast cancer. Finally, clinical evidence on antiandrogens is summarized along with strategies should be implemented to improve the medical management of these patients.",
keywords = "Androgen Antagonists, Animals, Antineoplastic Agents, Hormonal, Breast Neoplasms, Male, Humans, Male, Molecular Targeted Therapy, Neoplasms, Hormone-Dependent, Receptors, Androgen, Signal Transduction, Treatment Outcome, Journal Article, Review",
author = "{Di Lauro}, Luigi and Maddalena Barba and Laura Pizzuti and Patrizia Vici and Domenico Sergi and {Di Benedetto}, Anna and Marcella Mottolese and Valerie Speirs and Daniele Santini and {De Maria}, Ruggero and Marcello Maugeri-Sacc{\`a}",
note = "Copyright {\circledC} 2015 Elsevier Ireland Ltd. All rights reserved.",
year = "2015",
month = "11",
day = "1",
doi = "10.1016/j.canlet.2015.07.040",
language = "English",
volume = "368",
pages = "20--25",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Androgen receptor and antiandrogen therapy in male breast cancer

AU - Di Lauro, Luigi

AU - Barba, Maddalena

AU - Pizzuti, Laura

AU - Vici, Patrizia

AU - Sergi, Domenico

AU - Di Benedetto, Anna

AU - Mottolese, Marcella

AU - Speirs, Valerie

AU - Santini, Daniele

AU - De Maria, Ruggero

AU - Maugeri-Saccà, Marcello

N1 - Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Cancers arising in the male breast are uncommon. Male breast cancer is a hormone-driven disease that often expresses the estrogen receptor, and antiestrogen therapy represents the mainstay of treatment. Paradoxically, the advent of a wave of antiestrogens eclipsed the therapeutic potential of alternative therapeutic options. At the beginning of the hormonal therapy era the administration of antiandrogens to metastatic male breast cancer patients was proposed. Ever since the use of these compounds has largely been neglected. A therapeutic role for antiandrogens has been envisioned again in recent years. First, molecular characterization efforts pointed to the androgen receptor as a potential therapeutic target. Second, the development of aromatase inhibitors unexpectedly raised the need for neutralizing androgens in order to tackle endocrine feedback mechanisms responsible for acquired resistance. We herein provide an overview of molecular studies where the androgen receptor was investigated at the genomic, transcriptomic or phenotypic level. We then discuss androgens in the context of the endocrine networks nourishing male breast cancer. Finally, clinical evidence on antiandrogens is summarized along with strategies should be implemented to improve the medical management of these patients.

AB - Cancers arising in the male breast are uncommon. Male breast cancer is a hormone-driven disease that often expresses the estrogen receptor, and antiestrogen therapy represents the mainstay of treatment. Paradoxically, the advent of a wave of antiestrogens eclipsed the therapeutic potential of alternative therapeutic options. At the beginning of the hormonal therapy era the administration of antiandrogens to metastatic male breast cancer patients was proposed. Ever since the use of these compounds has largely been neglected. A therapeutic role for antiandrogens has been envisioned again in recent years. First, molecular characterization efforts pointed to the androgen receptor as a potential therapeutic target. Second, the development of aromatase inhibitors unexpectedly raised the need for neutralizing androgens in order to tackle endocrine feedback mechanisms responsible for acquired resistance. We herein provide an overview of molecular studies where the androgen receptor was investigated at the genomic, transcriptomic or phenotypic level. We then discuss androgens in the context of the endocrine networks nourishing male breast cancer. Finally, clinical evidence on antiandrogens is summarized along with strategies should be implemented to improve the medical management of these patients.

KW - Androgen Antagonists

KW - Animals

KW - Antineoplastic Agents, Hormonal

KW - Breast Neoplasms, Male

KW - Humans

KW - Male

KW - Molecular Targeted Therapy

KW - Neoplasms, Hormone-Dependent

KW - Receptors, Androgen

KW - Signal Transduction

KW - Treatment Outcome

KW - Journal Article

KW - Review

U2 - 10.1016/j.canlet.2015.07.040

DO - 10.1016/j.canlet.2015.07.040

M3 - Review article

C2 - 26276719

VL - 368

SP - 20

EP - 25

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 1

ER -